Azasite
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Meibomian Gland Dysfunction
Conditions
Meibomian Gland Dysfunction
Trial Timeline
Mar 1, 2013 → Jul 1, 2014
NCT ID
NCT01797107About Azasite
Azasite is a phase 2 stage product being developed by Merck for Meibomian Gland Dysfunction. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01797107. Target conditions include Meibomian Gland Dysfunction.
What happened to similar drugs?
0 of 1 similar drugs in Meibomian Gland Dysfunction were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01797107 | Phase 2 | Withdrawn |
| NCT00105534 | Phase 3 | Completed |
Competing Products
3 competing products in Meibomian Gland Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vehicle of TP-03 | Tarsus Pharmaceuticals | Phase 2 | 33 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2 | 29 |
| SHR8058 eye drops + saline eye drops. | Jiangsu Hengrui Medicine | Phase 3 | 40 |